L 95/34 Official Journal of the European Communities 15.4.2000 (Acts whose publication is not obligatory) COMMISSION COMMISSION DECISION of 28 July 1999 imposing fines for having supplied incorrect information in a notification submitted pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (Case No IV/M.1543 — Sanofi/Synthélabo) (notified under document number C(1999) 2290) (Only the French text is authentic) (Text with EEA relevance) (2000/291/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to the Agreement on the European Economic Area, and in particular Article 57 thereof, Having regard to Council Regulation (EEC) No 4064/89 of 21 December 1989 on the control of concentrations between undertakings ('), as amended by Regulation (EC) No 1310/ 97 (3 and in particular Article 14(1)(b) thereof, Having given the undertakings concerned the opportunity to make known their views on the objections raised by the Commission, Having regard to the opinion of the Advisory Committee on Concentrations, Whereas: (1)  Sanofi is a public limited liability company governed by French law, 53,61 % of whose shares are held directly or indirectly by Elf-Aquitaine, the remainder being held by private investors. Sanofi is active in three sectors: health products, i.e. mainly pharmaceutical products, but also diagnostic and animal health products, chemicals, and beauty products, where it produces and markets perfumes and cosmetics. () O] L 395, 30.12.1989, p. 1; corrigendum OJ L 257, 21.9.1990, p. 13. (» OJ L 180, 9.7.1997, p. 1; corrigendum O] L 40, 13.2.1998, p. 17. () Synthélabo is a public limited liability company governed by French law, 56,64 % of whose shares are held by L'Oreal, the remainder being held by private investors. Synthélabo is active in two sectors: health products, including pharmaceuticals and biomedical products, and chemicals. On 18 January 1999, Sanofi and Synthélabo notified their proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (the Merger Regu- lation). The notification was declared to be incomplete on 3 February 1999, since the replies to the question- naires sent by the Commission to competitors and customers pursuant to Article 11 had shown that infor- mation on one of the affected markets (platelet inhibi- tors) had not been provided. The parties then supplied the additional information requested by the Commis- sion, the notification took effect on 12 February 1999, and the merger was authorised by an Article 6(1)(b) decision on 15 March 1999 (the authorisation decision of 15 March 1999). Since the initial notification had indicated that there was no overlap or vertical links between the parties as regards active principles, the inquiry among competitors and customers did not deal with the impact of the merger on the markets for morphine and its derivatives and the decision of 15 March 1999 did not include any analysis of the impact of the merger in that area. The Commission subsequently received five complaints from